The Rise and Fall of Estrogen Therapy: Is Testosterone for “Manopause” Next?
Authors:
- Briana T. CostelloBCBriana T. Costello
- Keri SprungKSKeri Sprung
- Stephanie A. CoulterSCStephanie A. Coulter
- 1 October 2017
- journal article
- review article
- Published by Texas Heart Institute Journal in Texas Heart Institute Journal
- Vol. 44 (5) , 338-340
Abstract
Article Citation: Briana T. Costello, Keri Sprung, and Stephanie A. Coulter (2017) The Rise and Fall of Estrogen Therapy: Is Testosterone for “Manopause” Next?. Texas Heart Institute Journal: October 2017, Vol. 44, No. 5, pp. 338-340. https://doi.org/10.14503/THIJ-17-6360Keywords
This publication has 16 references indexed in Scilit:
- Re: Testosterone Products: Drug Safety Communication - FDA Cautions about Using Testosterone Products for Low Testosterone due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and StrokeJournal of Urology, 2015
- Disease Mongering of Age‐Associated Declines in Testosterone and Growth Hormone LevelsJournal of the American Geriatrics Society, 2015
- Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in MenPLOS ONE, 2014
- Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone LevelsJAMA, 2013
- Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trialsBMC Medicine, 2013
- Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2010
- Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men Are Differentially Linked to Age and Modifiable Risk Factors: The European Male Aging StudyThe Journal of Clinical Endocrinology & Metabolism, 2008
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Cardiovascular Disease Outcomes During 6.8 Years of Hormone TherapyJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998